Monograph
H03BA02 - Propylthiouracil |
Propably not porphyrinogenic |
PNP |
Rationale
Propylthiouracil is not metabolized by cyp-enzymes, nor does it induce or inhibit the activity of cyp-enzymes. Propylthiouracil has no potential porphyrogenic pharmacokinetic or pharmacodynamic properties.
Chemical description
Propylthiouracil is a thiourea anti thyroid drug. It inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine.
Therapeutic characteristics
Propylthiouracil is used in the management of hyperthyroidism. It is usually administered orally.
Metabolism and pharmacokinetics
Propylthiouracil undergoes rapid first-pass metabolism in the liver, and is mainly excreted in the urine as the glucuronic acid conjugate, with very little excreted as unchanged drug. It has an elimination half-life of 1-3 hours. Propylthiouracil is about 80% bound to plasma proteins. Propylthiouracil has no potential of pharmacokinetic drug interactions involving cyp-enzymes.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | DrugBank. Propylthiouracil.
|
|
| 2. | Sweetman SC, editor. Martindale: The complete drug reference. Propylthiouracil
|
|
| * | Summary of Product Characteristics | |
| 3. | Swedish medicines agency. Summary of Product Characteristics (SPC) Tiotil. (05.09.2011).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Serbia© NAPOS 2024